United Therapeutics (UTHR) Tops Q1 EPS by 55c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to United Therapeutics (UTHR) Tops Q1 EPS by 55c, Revenues Beat

United Therapeutics Corporation Reports First Quarter 2021 Financial Results

May 5, 2021 6:00 AM EDT

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 5, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2021. Total revenue in the first quarter of 2021 grew 6% year over year to $379.1 million, compared to $356.3 million in the first quarter of 2020.

"2021 is already a historic year for United Therapeutics, with the recent FDA approval and launch of Tyvaso for treatment of PH-ILD, submission of the Tyvaso DPI NDA, and the launch of our Remunity® Pump for Remodulin®," said Martine Rothblatt, Ph.D., Chairperson... More